GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aligos Therapeutics Inc (NAS:ALGS) » Definitions » Asset Turnover

Aligos Therapeutics (Aligos Therapeutics) Asset Turnover : 0.01 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aligos Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Aligos Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.99 Mil. Aligos Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $139.71 Mil. Therefore, Aligos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Aligos Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -183.64%. It is also linked to ROA % through Du Pont Formula. Aligos Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -99.81%.


Aligos Therapeutics Asset Turnover Historical Data

The historical data trend for Aligos Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aligos Therapeutics Asset Turnover Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - 0.02 0.07 0.10

Aligos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.06 0.03 0.02 0.01

Competitive Comparison of Aligos Therapeutics's Asset Turnover

For the Biotechnology subindustry, Aligos Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aligos Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's Asset Turnover falls into.



Aligos Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Aligos Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=15.529/( (146.693+151.527)/ 2 )
=15.529/149.11
=0.10

Aligos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0.986/( (151.527+127.902)/ 2 )
=0.986/139.7145
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Aligos Therapeutics  (NAS:ALGS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Aligos Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-139.452/75.938
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-139.452 / 3.944)*(3.944 / 139.7145)*(139.7145/ 75.938)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3535.8 %*0.0282*1.8398
=ROA %*Equity Multiplier
=-99.81 %*1.8398
=-183.64 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Aligos Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-139.452/139.7145
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-139.452 / 3.944)*(3.944 / 139.7145)
=Net Margin %*Asset Turnover
=-3535.8 %*0.0282
=-99.81 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Aligos Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Aligos Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Aligos Therapeutics (Aligos Therapeutics) Business Description

Traded in Other Exchanges
Address
One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Executives
Roche Finance Ltd 10 percent owner C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Matthew W. Mcclure officer: Chief Medical Officer C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Surplus Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Julian A. Symons officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Leonid Beigelman director, officer: President C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lucinda Y. Quan officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lawrence Blatt director, officer: Chief Executive Officer